Skip to content
value.today
Promis Neurosciences Inc. logo

Promis Neurosciences Inc.

PMN
$100 Mmarket cap on Oct 30, 2026+256.0% since Jan 2024
Compare
World rank
#18,728
Revenue
—
For year ending December-2025
Net income
$-40 M
SEC filing
Employees
—

Promis Neurosciences Inc. in brief

Promis Neurosciences Inc. is a listed company in the Biotechnology industry, based in Canada. Its market value was $100 M on 30 October 2026, which makes it the 18,728th largest listed company in the world and the 705th largest in Canada on this site. Neil K. Warma is its chief executive. Its shares trade under the symbol PMN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Promis Neurosciences Inc.

ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS’ technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.

From the company's annual report filed with the US SEC: read the report

Promis Neurosciences Inc. timeline

2 events, 2006–2014
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. ✎
    Renamed ProMIS Neurosciences Inc.
    Formerly Amorfix Life Sciences Ltd.

Events of Promis Neurosciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$36 M$72 M$108 M$144 M2023202420252026

World rank over time

▲ up 7,683 places since 2022
2022-01-07: #26469#26,46920222022-12-25: #26178#26,17820222023-07-30: #26445#26,44520232024-01-05: #27548#27,54820242026-03-08: #10963#10,96320262026-08-01: #16563#16,56320262026-10-14: #19764#19,76420262026-10-30: #18786#18,7862026

Rank in Canada: #961 (Jan 2022) · #839 (Dec 2022) · #828 (Jul 2023) · #893 (Jan 2024) · #48 (Mar 2026) · #492 (Aug 2026) · #782 (Oct 2026) · #705 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-17.1%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
113.7%
Net debt
$-13M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-10M—FY21Fiscal year ending Dec 2022: revenue —, net income $-18M—FY22Fiscal year ending Dec 2023: revenue —, net income $-13M—FY23Fiscal year ending Dec 2024: revenue —, net income $3M—FY24Fiscal year ending Dec 2025: revenue —, net income $-40M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-40M$-40M—
Dec 2024——$-17M$3M—
Dec 2023——$-14M$-13M—
Dec 2022——$-23M$-18M—
Dec 2021——$-8M$-10M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-28M——$-22.61—
Dec 2024$-27M——$2.63—
Dec 2023$-11M——$-1.07—
Dec 2022$-17M$0M$-17M$-2.41—
Dec 2021$-9M$0M$-9M$-1.69—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-0M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-10M—Jun ’25Three months to Sep 2025: revenue —, net income $-12M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-11M—Dec ’25Three months to Mar 2026: revenue —, net income $-8M—Mar ’26Three months to Jun 2026: revenue —, net income $-12M—Jun ’26Three months to Sep 2026: revenue —, net income $-8M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Promis Neurosciences Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-40 M
Net income
$-40 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$9 M
Total liabilities
$10 M
Total equity
$-1 M

As of December-2025

Top 31 institutional investors in Promis Neurosciences Inc.#

As of Sep 30, 2026
31 institutions held 6.4 M shares (about 70.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 62.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Promis Neurosciences Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.1,292,657—14.37%$14 MNov 16, 2026
2Deep Track Capital, LP740,117-95,538 (-11.43%)8.23%$8 MNov 16, 2026
3Wellington Management Group LLP696,3780 (0.00%)7.74%$8 MNov 16, 2026
4Ally Bridge Group (NY) LLC620,3190 (0.00%)6.89%$7 MNov 16, 2026
5Adage Capital Partners GP, L.L.C.564,275+400,000 (+243.49%)6.27%$6 MNov 16, 2026
6Trails Edge Capital Partners, LP557,1030 (0.00%)6.19%$6 MNov 16, 2026
7Yu Fan329,7600 (0.00%)3.67%$4 MNov 16, 2026
8Woodline Partners LP314,601-127,310 (-28.81%)3.50%$3 MNov 16, 2026
9Sphera Funds Management LTD.254,782-70,809 (-21.75%)2.83%$3 MNov 16, 2026
10683 Capital Management, LLC250,000+155,000 (+163.16%)2.78%$3 MNov 16, 2026
11Ikarian Capital, LLC205,0000 (0.00%)2.28%$2 MNov 16, 2026
12Ameriprise Financial Inc185,7000 (0.00%)2.06%$2 MNov 16, 2026
13Millennium Management LLC121,123+65,078 (+116.12%)1.35%$1 MNov 16, 2026
14ADAR1 Capital Management, LLC92,8500 (0.00%)1.03%$1 MNov 16, 2026
15Boothbay Fund Management, LLC62,0780 (0.00%)0.69%$1 MNov 16, 2026
16Citadel Advisors LLC22,902New0.25%$0 MNov 16, 2026
17Two Sigma Investments, LP16,228New0.18%$0 MNov 16, 2026
18Jane Street Group, LLC14,621New0.16%$0 MNov 12, 2026
19Quadrature Capital Ltd11,615New0.13%$0 MNov 13, 2026
20Seven Fleet Capital Management LP10,6000 (0.00%)0.12%$0 MNov 16, 2026
21Morgan Stanley7,5590 (0.00%)0.08%$0 MNov 13, 2026
22Osaic Holdings, Inc.3600 (0.00%)0.00%$0 MNov 12, 2026
23Jpmorgan Chase & Co285New0.00%$0 MNov 12, 2026
24Royal Bank Of Canada2180 (0.00%)0.00%$0 MNov 16, 2026
25Steward Partners Investment Advisory, LLC940 (0.00%)0.00%$0 MNov 13, 2026
Show all 31: investors 26 to 31
Institutional investors 26 to 31 in Promis Neurosciences Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Tower Research Capital LLC (TRC)33New0.00%$0 MNov 16, 2026
27Caitong International Asset Management Co., Ltd10+7 (+233.33%)0.00%$0 MOct 29, 2026
28Federation des caisses Desjardins du Quebec100 (0.00%)0.00%$0 MNov 16, 2026
29TD Waterhouse Canada Inc.50 (0.00%)0.00%$0 MOct 16, 2026
30National Bank Of Canada /fi/2New0.00%$0 MNov 16, 2026
31UBS Group AG1-690 (-99.86%)0.00%$0 MNov 10, 2026

Mutual funds holding Promis Neurosciences Inc.#

1 funds hold shares worth $0 M. Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Promis Neurosciences Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,676$0 M—<0.01%+1550%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Promis Neurosciences Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$8.9 M
11 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$8.9 M
open market only
Insiders on file
14
since
$8.5 M$0Jul 2024: bought $0 (3 trades), sold $0 (0 trades)Jul 24Aug 2024: bought $13 K (1 trades), sold $0 (0 trades)Sep 2024: bought $372 K (5 trades), sold $0 (0 trades)SepFeb 2025: bought $15 K (1 trades), sold $0 (0 trades)Jun 2025: bought $0 (0 trades), sold $0 (1 trades)JunOct 2025: bought $15 K (1 trades), sold $0 (0 trades)Feb 2026: bought $8.5 M (2 trades), sold $0 (0 trades)FebMar 2026: bought $141 K (4 trades), sold $0 (0 trades)Apr 2026: bought $45 K (1 trades), sold $0 (0 trades)AprAug 2026: bought $30 K (1 trades), sold $0 (0 trades)Oct 2026: bought $5 K (1 trades), sold $0 (0 trades)OctNov 2026: bought $129 K (2 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Promis Neurosciences Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Eugene WilliamsDirectorBuy+26,500$3.430$91 K40,213Form 4
filed Neil CashmanChief Scientific Officer, DirectorBuy+10,000$3.860$39 K14,532Form 4
filed Eugene WilliamsDirectorBuy+1,316$3.990$5 K13,713Form 4
filed Johanne KaplanChief Development OfficerBuy+2,280$13.30$30 K6,221Form 4
filed Patrick D. KirwinDirectorBuyindirect+4,000$11.33$45 K4,653Form 4
filed Eugene WilliamsDirectorBuy+2,000$24.40$49 K12,397Form 4
filed Eugene WilliamsDirectorBuy+2,000$24.00$48 K10,397Form 4
filed Eugene WilliamsDirectorBuy+1,000$21.89$22 K8,397Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Promis Neurosciences Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
274,761
12.8% of shares · 1.54 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2,500 reverse split

Trading halts

  • 2026-11-02 14:40 UTC, code LUDP, resumed 14:45 UTC
  • 2026-11-02 14:31 UTC, code LUDP, resumed 14:36 UTC
  • 2026-10-30 16:12 UTC, code LUDP, resumed 16:22 UTC
  • 2026-01-30 15:09 UTC, code LUDP, resumed 15:14 UTC
  • 2026-01-30 14:33 UTC, code LUDP, resumed 14:38 UTC

Fails to deliver

  • : 102 shares at $11.08
  • : 3,398 shares at $9.68
  • : 465 shares at $8.05
  • : 62 shares at $8.34
  • : 908 shares at $8.29

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Promis Neurosciences Inc. scorecard#

Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-17.1%Free cash flow is -17.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-22.61 vs 2.63Diluted EPS -22.61 in fiscal 2025 against 2.63 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$40 MNet income -$40 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.9×Current ratio 0.88 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year66.1%Diluted shares up 66.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Promis Neurosciences Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Promis Neurosciences Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Research and development33117.9164.6
General and administrative6.86.26.47.33.7
Operating expenses401714238.3
Operating income−40−17−14−23−8.3
Interest expense and finance costs———0.30.4
Other non-operating income (expense)0.4201.15.3−1.5
Income tax—000—
Net income including minority interests−402.8−13−18−9.8
Net income attributable to shareholders−402.8−13−18−9.8
Earnings per share, basic-22.612.68r-1.07-2.41-1.69
Earnings per share, diluted-22.612.63r-1.07-2.41-1.69
Shares, weighted average (basic)1.81.0r127.55.8
Shares, weighted average (diluted)1.81.1r127.55.8
Balance sheet
Cash and cash equivalents6.113135.917
Short-term investments0.00.00.00.00.0
Other current assets3.05.61.01.00.7
Current assets9.219146.918
Property, plant and equipment———0.00.0
Other intangible assets———0.00.0
Total assets9.219146.918
Accounts payable2.51.77.83.00.4
Current liabilities102.29.36.40.9
Total liabilities102.49.98.312
Retained earnings−130−91−93−80−62
Shareholders' equity−1.3163.8−1.35.7
Total liabilities and equity9.219146.918
Shares outstanding2.21.3r198.67.2
Cash-flow statement
Share-based compensation0.90.80.30.50.5
Cash from operating activities−28−27−11−17−9.3
Capital expenditure———−0.0−0.0
Cash from investing activities−0.0−0.0−0.0−0.00.1
Shares issued0.70.2—5.016
Cash from financing activities2128186.526
Change in cash−7.20.76.7−1116
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Promis Neurosciences Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Promis Neurosciences Inc.: countries of operation
CountryPresenceRevenue there
🇨🇦 CanadaHeadquarters1 office—
🇺🇸 USA1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Promis Neurosciences Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 5 · Material agreement 5 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8

Promis Neurosciences Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Promis Neurosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2022$7 MNo. 4$2 to $10 million23equity, optionsSEC
Aug 2021$18 MNo. 3$10 to $50 million34equity, optionsSEC
Mar 2021$7 MNo. 2$2 to $10 million7equity, debt, optionsSEC
Apr 2018$2 MNo. 1Under $2 million18equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Promis Neurosciences Inc. compares in Biotechnology

  • Market cap$100 M · higher than 36% of 726
  • FCF yield-17.1% · higher than 47% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Promis Neurosciences Inc.🇨🇦$100 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Promis Neurosciences Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Promis Neurosciences Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Promis Neurosciences Inc.? Suggest a correction